B. Riley analyst Mayank Mamtani raised the firm’s price target on Novavax (NVAX) to $18 from $16 and keeps a Buy rating on the shares. Activist pressure on governance and costs makes a partial board refresh and further balance sheet enhancements likely, the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVAX: